Alternative Prostate Cancer Screening Strategies
Authors: Michel Labrecque, Armen Aprikian
Journal: Annals of Internal Medicine (2013)

Letters21 May 2013Alternative Prostate Cancer Screening StrategiesMichel Labrecque, MD, PhD and Armen Aprikian, MDMichel Labrecque, MD, PhDFrom Laval University, Québec City, Québec, Canada, and McGill University, Montreal, Québec, Canada.Search for more papers by this author and Armen Aprikian, MDFrom Laval University, Québec City, Québec, Canada, and McGill University, Montreal, Québec, Canada.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-158-10-201305210-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Gulati and colleagues (1) propose estimates of lifetime risk for prostate cancer for 35 screening strategies versus no screening. On the basis of their analysis, the lifetime risk for prostate cancer diagnosis in a 50-year-old man undergoing annual prostate-specific antigen (PSA) screening until age 69 years with a PSA threshold for referral for further investigation of 4.0 µg/L (the most effective strategy to minimize overdiagnosis, according to the authors) would be 13.8%, whereas the lifetime risk for a 50-year-old man not undergoing screening would be 12.0% (difference in risk, 1.8%). These numbers seem surprisingly low considering that ...References1. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen–based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med. 2013;158:145-53. [PMID: 23381039] LinkGoogle Scholar2. National Cancer Institute. DevCan-Probability of Developing or Dying of Cancer. 2012. Accessed at http://surveillance.cancer.gov/devcan/ on 13 March 2013. Google Scholar3. Wever EM, Hugosson J, Heijnsdijk EA, Bangma CH, Draisma G, de Koning HJ. To be screened or not to be screened? Modeling the consequences of PSA screening for the individual. Br J Cancer. 2012;107:778-84. [PMID: 22805324] CrossrefMedlineGoogle Scholar4. Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med. 2012;367:595-605. [PMID: 22894572] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Michel Labrecque, MD, PhD; Armen Aprikian, MDAffiliations: From Laval University, Québec City, Québec, Canada, and McGill University, Montreal, Québec, Canada.Disclosures: Dr. Labrecque: Consultancy: Collège des Médecins du Québec. Dr. Aprikian: Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like: Collège des Médecins du Québec; Consultancy: Ferring, Sanofi, AstraZeneca, Amgen, Abbott, Paladin. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoComparative Effectiveness of Alternative Prostate-Specific Antigen–Based Prostate Cancer Screening Strategies Roman Gulati , John L. Gore , and Ruth Etzioni Alternative Prostate Cancer Screening Strategies Roman Gulati and Ruth Etzioni Metrics 21 May 2013Volume 158, Issue 10Page: 778KeywordsAntigensCancer screeningConflicts of interestProstate cancerStatistical dataSurveillance Epidemiology and End Results ePublished: 21 May 2013 Issue Published: 21 May 2013 Copyright & PermissionsCopyright © 2013 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...